Would the Cheap Versions of Oral COVID-19 Antiviral Bring New Opportunities for Chinese Companies?
Some Chinese companies are allowed to make cheap versions of Merck’s molnupiravir based on the MPP agreement.We analyzed the impact and outlook,...
243 Views
Pre-IPO Apollomics - Concerns on Competition and Commercialization Despite Some Promising Products
This article provided insights on its major products in the pipeline in terms of competitive landscape, strength and challenges, as well as...
614 Views
Ascletis Pharma: Invalidation of Gilead Patents Won't Help
China's State Intellectual Property Office (SIPO) last week invalidated Gilead Sciences (GILD US) 's patent claims on the base compound for...
825 Views